Navigation Links
Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
Date:7/14/2014

RESEARCH TRIANGLE PARK, N.C., July 14, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today the expansion of its drug design and development program. The company has been granted supercomputing time at Argonne National Laboratory to design inhibitors of multiple parasitic targets. 

Through a discretionary allocation of 1 million core-hours at the Argonne Leadership Computing Facility (ALCF), researchers at Cloud Pharmaceuticals will use Mira, a 10-petaflops IBM Blue Gene/Q supercomputer to investigate inhibitors of the dihydrofolate reductase enzyme, or DHFR, from multiple sources. The purpose is to identify leading drug candidates for broad-impact, anti-parasitic therapeutics targeting several orphan diseases including malaria. The results will be published to the scientific community and general public. Preclinical development is expected to follow.

"Very often, the same protein will mutate and cause different types of illness or disease. Targeting this protein at a molecular level helps to identify a more effective treatment protocol," says Ed Addison, CEO of Cloud Pharmaceuticals.

Cloud Pharmaceuticals is using a highly parallel, quantum mechanics/molecular mechanics (QM/MM) computational chemistry algorithm and bioinformatics tools to increase the accuracy of the algorithms used in drug discovery. Cloud Pharmaceuticals also uses its Inverse Design in silico drug design technology and applies novel artificial intelligence algorithms to search through large portions of molecular space to identify the best drug candidates.

About Cloud Pharmaceuticals, Inc.

Cloud Pharmaceuticals is a leader in the computational design of new drugs and subsequent rapid, information-driven drug development. We accelerate the drug discovery and design process in a way that delivers tangible results and true value for our partners. For information visit www.cloudpharmaceuticals.com.


'/>"/>
SOURCE Cloud Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. ScaleMatrix Leads the Way Unveiling the Industry’s First Transparent Pricing Tool in Private Cloud Offerings
2. Healthcare Cloud Computing (Clinical, EMR, SaaS, Private, Public, Hybrid) Market - Global Trends, Challenges, Opportunities & Forecasts (2012 - 2017)
3. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
4. MUSA's Validated Cloud: Fully Qualified Citrix® Application Delivery - IQ & OQ Library Now Includes: NetScaler® & XenApp®
5. Salk scientists use Amazon Cloud to view molecular machinery in remarkable detail
6. Adeptia Named a Value Leader in EMA Radar for Integration Technologies for Hybrid Cloud: Q4 2012
7. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
8. Chemical Publishing Company Partners with Author Cloudware for a Digital eBook Distribution for Water Treatment, Waste Water Treatment, and Cooling Water Treatment Titles
9. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
10. Spaulding Clinical to Showcase First Cloud-based Cardiac Safety Solution Fully Integrated with Medidata Clinical Cloud at DIA
11. Controlling magnetic clouds in graphene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/9/2016)... DelveInsight,s, "Protein-Tyrosine Phosphatase ... in depth insights on the pipeline drugs ... Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s Report ... of development including Discovery, Pre-clinical, IND, Phase ... Report covers the product clinical trials information ...
(Date:2/8/2016)... DELHI , February 8, 2016 ... Invictus Oncology Private Limited, an innovation-driven oncology company ... effective and less toxic, today announced that chairman ... Tata, has invested in the company as part ... financing round, joining existing investors Navam Capital and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( IMS ) is pleased ... a completely new technical foundation and is so significant it was endowed with a ... increased speed for search results, a streamlined layout and a more intuitive format for ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016  BioMEMS devices deployed in ... on medical screening and diagnostic applications, such ... devices that facilitate and assure continuous monitoring ... are being bolstered through new opportunities offered ... acquisition coupled with wireless connectivity and low ...
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) announces ... personality, Joey Fatone . Las Vegas , ... --> Las Vegas , where Joey appeared ... The new video ad was filmed at the Consumer Electronics Show ... the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):